HC Wainwright Has Negative View of Biomea Fusion Q2 Earnings

Biomea Fusion, Inc. (NASDAQ:BMEA) – Investment analysts at HC Wainwright reduced their Q2 2026 earnings per share (EPS) estimates for shares of Biomea Fusion in a report released on Tuesday, May 12th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.17) per share for the quarter, down from their previous forecast of ($0.14). The consensus estimate for Biomea Fusion’s current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for Biomea Fusion’s Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.67) EPS and FY2028 earnings at ($0.82) EPS.

Other analysts also recently issued reports about the company. Citizens Jmp initiated coverage on Biomea Fusion in a research note on Tuesday, May 5th. They set a “market outperform” rating and a $9.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biomea Fusion in a research note on Monday, April 20th. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Biomea Fusion in a research note on Tuesday, April 28th. Citigroup began coverage on Biomea Fusion in a research note on Tuesday, May 5th. They set an “outperform” rating for the company. Finally, Wall Street Zen raised Biomea Fusion from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.29.

Biomea Fusion Stock Down 6.3%

BMEA opened at $1.48 on Thursday. The business has a 50 day moving average price of $1.55 and a two-hundred day moving average price of $1.38. The company has a market cap of $107.00 million, a PE ratio of -2.18 and a beta of -0.32. Biomea Fusion has a 52 week low of $0.87 and a 52 week high of $3.08.

Biomea Fusion (NASDAQ:BMEA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.07.

Hedge Funds Weigh In On Biomea Fusion

A number of large investors have recently modified their holdings of BMEA. Marshall Wace LLP raised its stake in shares of Biomea Fusion by 293.7% during the 4th quarter. Marshall Wace LLP now owns 1,160,351 shares of the company’s stock worth $1,439,000 after buying an additional 865,618 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Biomea Fusion in the 4th quarter worth approximately $783,000. Mariner LLC grew its holdings in shares of Biomea Fusion by 145.1% in the 4th quarter. Mariner LLC now owns 585,632 shares of the company’s stock worth $726,000 after acquiring an additional 346,702 shares during the period. Vanguard Group Inc. grew its holdings in shares of Biomea Fusion by 15.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,170,066 shares of the company’s stock worth $4,384,000 after acquiring an additional 290,376 shares during the period. Finally, AQR Capital Management LLC grew its holdings in shares of Biomea Fusion by 670.5% in the 1st quarter. AQR Capital Management LLC now owns 264,028 shares of the company’s stock worth $562,000 after acquiring an additional 229,763 shares during the period. 96.72% of the stock is owned by hedge funds and other institutional investors.

Biomea Fusion Company Profile

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.